title: Tissue specific changes in acyl-CoA: cholesterol acyltransferase (ACAT) mRNA levels in rabbits.
abstract: A human cDNA clone (K1) was recently isolated that encodes functional acyl-CoA:cholesterol acyltransferase (ACAT) protein (Chang et al. J. Biol. Chem. 1993. 268: 20747-20755). We used the K1 clone to screen a rabbit liver cDNA library and isolated a 919 base pair partial rabbit cDNA (ACAT14b) that was greater than 90% homologous with the human nucleotide sequence. Northern blotting using the rabbit ACAT cDNA14b revealed the existence of at least six related mRNA species (ranging from 6.2 to 1.7 kb) in various rabbit tissues. Using an RNAse protection assay, ACAT mRNA14b was detected in twelve separate rabbit organs. Adrenal gland contained the highest concentrations of ACAT mRNA14b (per microgram of total RNA) being 20-, 30-, and 50-fold higher than small intestine, aorta, and liver, respectively. Additional studies with isolated liver cell populations revealed that rabbit hepatic nonparenchymal cells contained 30-fold more ACAT mRNA14b (per microgram of total RNA) than parenchymal cells. To determine whether ACAT mRNA14b levels are regulated in vivo, rabbits were fed for 4 weeks a high fat/high cholesterol diet (HFHC; 0.5% cholesterol, 3% coconut oil, 3% peanut oil) at which point they were either kept for an additional 4 weeks on the HFHC-diet or switched to the HFHC-diet plus CI-976 (50 mg/kg), a potent and specific ACAT inhibitor; another group of rabbits was fed a chow diet for the entire 8 weeks. The HFHC-diet caused a 2- and 3-fold increase in hepatic and aortic ACAT mRNA14b levels, respectively, in comparison to chow-fed animals; there was no change in adrenal or small intestine levels. CI-976 treatment lowered ACAT mRNA14b levels by 60% and 40% in liver and aorta, respectively, in comparison to the HFHC controls; again there was no change in adrenal or small intestine levels. These data indicate that ACAT mRNA14b levels increase in a tissue specific manner in response to dietary fat and cholesterol.
authors.affiliation: Division of Therapeutics, Parke-Davis Pharmaceutical Research Division, Ann Arbor, MI 48105, USA.
authors.forename: M E
authors.initials: ME
authors.lastname: Pape
authors.forename: P A
authors.initials: PA
authors.lastname: Schultz
authors.forename: T J
authors.initials: TJ
authors.lastname: Rea
authors.forename: R B
authors.initials: RB
authors.lastname: DeMattos
authors.forename: K
authors.initials: K
authors.lastname: Kieft
authors.forename: C L
authors.initials: CL
authors.lastname: Bisgaier
authors.forename: R S
authors.initials: RS
authors.lastname: Newton
authors.forename: B R
authors.initials: BR
authors.lastname: Krause
mesh_terms: D000818:Animals; D001483:Base Sequence; D003001:Cloning, Molecular; D018076:DNA, Complementary / Q000235:genetics / Q000302:isolation & purification; D004041:Dietary Fats / Q000008:administration & dosage; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D008099:Liver / Q000201:enzymology; D008969:Molecular Sequence Data; D009928:Organ Specificity; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011817:Rabbits; D016415:Sequence Alignment; D002785:Sterol O-Acyltransferase / Q000235:genetics* / Q000378:metabolism*
chemical_list: D018076:DNA, Complementary; D004041:Dietary Fats; D012333:RNA, Messenger; D002785:Sterol O-Acyltransferase